JPRN-UMIN000051596尚未招募Unknown
Establishment of an international method of Association Therapy for prevention of frailty in the older people at home and varification of its effectiveness. - Establishment of an international method of Association Therapy for prevention of frailty in the older people at home and varification of its effectiveness.
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclude persons under 65 years of age, incapable of writing or literacy in their native language, those with serious physical or mental illness, and those with severe audiovisual disabilities.
研究者
相似试验
进行中（未招募）
不适用
An International Single-Arm Protocol to Provide Expanded Access to VELCADE(TM) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma - Expanded Access Program to VELCADEPatients with multiple myeloma who have received at least 2 previous lines of therapy and are refractory to or have relapsed after their last therapy for multiple myelomaClassification code 10028228EUCTR2004-001178-13-LVJanssen Cilag International NV750
进行中（未招募）
不适用
An International Single-Arm Protocol to Provide Expanded Access to VELCADE(TM) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma - Expanded Access Program to VELCADE(TM) (EAP)EUCTR2004-001178-13-LTJanssen Cilag International N.V.750
进行中（未招募）
1 期
An International Single-Arm Protocol to Provide Expanded Access to VELCADE(TM) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma - Expanded Access Program to VELCADE(TM) (EAP)EUCTR2004-001178-13-CZJanssen-Cilag, div.Johnson and Johnson s.r.o.
尚未招募
不适用
A study following people with haemophilia A and B, with or without inhibitors, when on usual treatment (explorerââ??¢6)CTRI/2019/03/018292ovo Nordisk India Private Ltd
尚未招募
Unknown
A study to validate an antiemesis questionnaire tool in blood cancer patients receiving chemotherapyCTRI/2020/10/028252ot Applicable